Impact of Parkinson's disease risk loci on age at onset

Movement Disorders

Volumn 30, Issue 6, 2015, Pages 847-850

  Lill, Christina M ^a   Hansen, Johnni ^b,c   Olsen, Jørgen H ^b   Binder, Harald ^d   Ritz, Beate ^c   Bertram, Lars ^a,e  

^a UNIVERSITY OF LÜBECK   (Germany)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Age at onset; DGKQ; GAK; GBA; Genetic association; Genetic risk score; Genome wide association study, GWAS; N370S; Parkinson's disease, PD

Indexed keywords

CYCLIN G; CYCLIN G ASSOCIATED KINASE; MEMBRANE PROTEIN; TRANSMEMBRANE PROTEIN 175; UNCLASSIFIED DRUG; BETA GLUCOSIDASE; GAK PROTEIN, HUMAN; POTASSIUM CHANNEL; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TMEM175 PROTEIN, HUMAN;

ALLELE; ARTICLE; FAMILY HISTORY; GBA GENE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; ONSET AGE; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; AGED; DENMARK; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; BETA-GLUCOSIDASE; DENMARK; FEMALE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LINEAR MODELS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; POTASSIUM CHANNELS; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS;

EID: 84929654195     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26237     Document Type: Article

References (10)

1. Hamza TH, Payami H. The heritability of risk and age at onset of Parkinson's disease after accounting for known genetic risk factors. J Hum Genet 2010;55:241-243.
2. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014;46:989-993.
3. Ahmed I, Lee PC, Lill CM, et al. Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease. PLoS Genet 2014;10:e1004788.
4. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
5. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
6. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061-1073.
7. International Schizophrenia Consortium, Purcell SM, Wray NR, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460:748-752.
8. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-1661.
9. Chahine LM1, Qiang J, Ashbridge E, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol 2013;70:852-858.
10. Alcalay RN, Dinur T, Quinn T, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 2014;71:752-757.